Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of Oncology ◽

10.1016/j.annonc.2020.04.001 ◽

2020 ◽

Vol 31 (7) ◽

pp. 942-950 ◽

Author(s):

R.L. Ferris ◽

R. Haddad ◽

C. Even ◽

M. Tahara ◽

M. Dvorkin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Annals of Oncology ◽

10.1093/annonc/mdy424.045 ◽

2018 ◽

Vol 29 ◽

pp. viii729 ◽

Author(s):

B. Burtness ◽

K.J. Harrington ◽

R. Greil ◽

D. Soulières ◽

M. Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

339TiP Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)

Annals of Oncology ◽

10.1093/annonc/mdv527.26 ◽

2015 ◽

Vol 26 ◽

pp. ix93

Author(s):

C.S. Hu ◽

A. Chan ◽

L. Gao ◽

M.-J. Ahn ◽

E. Cohen ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Adjuvant Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Phase Iii Study ◽

Download Full-text

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

10.1016/s0140-6736(18)31999-8 ◽

2019 ◽

Vol 393 (10167) ◽

pp. 156-167 ◽

Author(s):

Ezra E W Cohen ◽

Denis Soulières ◽

Christophe Le Tourneau ◽

José Dinis ◽

Lisa Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

The Lancet Oncology ◽

10.1016/s1470-2045(18)30350-4 ◽

2018 ◽

Vol 19 (8) ◽

pp. 1082-1093 ◽

Author(s):

Douglas Adkins ◽

Paul Mehan ◽

Jessica Ley ◽

Marilyn J Siegel ◽

Barry A Siegel ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Open Label Phase ◽

Download Full-text

A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Annals of Oncology ◽

10.1016/s0923-7534(20)32015-9 ◽

2012 ◽

Vol 23 ◽

pp. xi35 ◽

Author(s):

T.Y. Seiwert ◽

J. Fayette ◽

D. Cupissol ◽

J.M. DelCampo ◽

P.M. Clement ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Neck Squamous Cell Carcinoma ◽

Open Label Phase

Download Full-text

KEYNOTE-048: A Phase III Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Default Digital Object Group ◽

10.1200/adn.19.190258 ◽

2019 ◽

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1088 ◽

2020 ◽

Vol 31 ◽

pp. S683-S684

Author(s):

L.L. Siu ◽

B. Burtness ◽

E.E. Cohen ◽

K.J. Harrington ◽

L.F. Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)

Annals of Oncology ◽

10.1093/annonc/mdy287.078 ◽

2018 ◽

Vol 29 ◽

pp. viii398 ◽

Author(s):

J.-P. Machiels ◽

L. Licitra ◽

Y.G. Tao ◽

C.-J. Yen ◽

D. Rischin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Neck Squamous Cell Carcinoma ◽

Phase Iii ◽

Advanced Head ◽

Phase Iii Study

Download Full-text

Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis

Annals of Oncology ◽

10.1093/annonc/mdw435.18 ◽

2016 ◽

Vol 27 ◽

pp. vi563 ◽

Author(s):

J. Huang ◽

Y. Liu ◽

S. Dai ◽

P. Lu ◽

Y. Ba ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Interim Analysis ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.11.144 ◽

2020 ◽

Vol 106 (5) ◽

pp. 1182-1183

Author(s):

O. Ronen ◽

M. Shickler ◽

H. Reuveni ◽

I. Israel ◽

I. Haviv ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Escalation ◽

Neck Squamous Cell Carcinoma ◽

Safety And Efficacy ◽

Download Full-text